Geetika Sethi
Overview
Explore the profile of Geetika Sethi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radovich M, Pickering C, Felau I, Ha G, Zhang H, Jo H, et al.
Cancer Cell
. 2018 Feb;
33(2):244-258.e10.
PMID: 29438696
Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among TETs, thymoma is the most predominant, characterized by a unique association with autoimmune diseases, followed by thymic carcinoma,...
2.
Pathak H, Zhou Y, Sethi G, Hirst J, Schilder R, Golemis E, et al.
PLoS One
. 2015 Dec;
10(12):e0144126.
PMID: 26637171
Molecular targeted therapies have been the focus of recent clinical trials for the treatment of patients with recurrent epithelial ovarian cancer (EOC). The majority have not fared well as monotherapies...
3.
Sethi G, Chopra G, Samudrala R
Mini Rev Med Chem
. 2015 Feb;
15(8):705-17.
PMID: 25694071
We have examined the effect of eight different protein classes (channels, GPCRs, kinases, ligases, nuclear receptors, proteases, phosphatases, transporters) on the benchmarking performance of the CANDO drug discovery and repurposing...
4.
Sethi G, Kwon Y, Burkhalter R, Pathak H, Madan R, McHugh S, et al.
Mol Carcinog
. 2014 Nov;
54(12):1772-85.
PMID: 25418856
Molecular vulnerabilities represent promising candidates for the development of targeted therapies that hold the promise to overcome the challenges encountered with non-targeted chemotherapy for the treatment of ovarian cancer. Through...
5.
Sharma P, Stecklein S, Kimler B, Sethi G, Petroff B, Phillips T, et al.
J Cancer Ther Res
. 2014 Sep;
3(2):1-11.
PMID: 25177489
Introduction: Methylation of the promoter is frequent in triple negative breast cancers (TNBC) and results in a tumor phenotype similar to -mutated tumors. mutation-associated cancers are more sensitive to DNA...
6.
Minie M, Chopra G, Sethi G, Horst J, White G, Roy A, et al.
Drug Discov Today
. 2014 Jul;
19(9):1353-63.
PMID: 24980786
The Computational Analysis of Novel Drug Opportunities (CANDO) platform (http://protinfo.org/cando) uses similarity of compound-proteome interaction signatures to infer homology of compound/drug behavior. We constructed interaction signatures for 3733 human ingestible...
7.
Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin A
Proc Natl Acad Sci U S A
. 2014 Jan;
111(2):711-6.
PMID: 24379393
During tumor development, constant interplay occurs between tumor cells and surrounding stromal cells. We report evidence that gastrointestinal stromal tumor (GIST) cells invade the interstitial stroma through the release of...
8.
Pessetto Z, Weir S, Sethi G, Broward M, Godwin A
Mol Cancer Ther
. 2013 May;
12(7):1299-309.
PMID: 23657945
Despite significant treatment advances over the past decade, metastatic gastrointestinal stromal tumor (GIST) remains largely incurable. Rare diseases, such as GIST, individually affect small groups of patients but collectively are...
9.
Sethi G, Pathak H, Zhang H, Zhou Y, Einarson M, Vathipadiekal V, et al.
PLoS One
. 2012 Oct;
7(10):e47086.
PMID: 23056589
Targeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of...